Tue, 28 February 2017
The cast looks at the latest earnings results for major department stores as a tough retail environment and major store closures dominate the headlines. They also reach into the mailbag to take a first look at VF Corporation. |
Mon, 27 February 2017
A mortgage is many homeowners single biggest expense each month, so it pays to understand the costs -- especially for new home buyers and people searching for a lower rate to refinance their house. The Trump administration could affect mortgage costs throughout 2017. Join the Motley Fool’s Nathan Hamilton and Gaby Lapera to learn what you need to know about mortgages in 2017. |
Fri, 24 February 2017
Digging through the company's earnings release, we break down what went wrong for Fitbit last year, and what management is doing to turn things around and find growth in 2017. |
Thu, 23 February 2017
Energy storage is a hot topic these days, here’s who is currently leading the charge. |
Wed, 22 February 2017
Carl Icahn's reportedly focusing his brand of investor activism on Bristol-Myers Squibb, but it's anyone's guess if he'll be able to convince the company to sell. Also, Celgene delivers a phase 3 win with blockbuster implications. |
Tue, 21 February 2017
From price wars to automation, Fool.com contributor Daniel Kline offers his take on major trends currently driving innovation and growth at your favorite quick service restaurants. |
Fri, 17 February 2017
Snap is one of the hottest potential IPO's of 2017. Now that we've had a chance to look at the numbers, should investors keep it on their watch list once shares start trading? |
Thu, 16 February 2017
BP plc has released its 2017 Energy Outlook that extends to 2035. For long-term investors, BP's opinions may be both surprising and thought-provoking. |
Wed, 15 February 2017
In this Valentine's Day edition, we explore cholesterol busters, heart surgery, and the latest in anticoagulants. |
Tue, 14 February 2017
Dave was just a business school student when he and his friends decided to start an eyewear company that would eventually revamp the entire industry. Now serving as co-CEO of Warby Parker, he shares his story and offers some insight into the state of retail. Thanks to Audible for supporting our podcast. Get a free audiobook with a free 30-day trial at audible.com/fool. |
Mon, 13 February 2017
The Dodd-Frank Act dramatically transformed the bank industry when it was passed in 2010. But fast forward to today and President Trump is promising to make it a thing of the past. On this week's episode of Industry Focus, Gaby and John provide a comprehensive look at not only the history and purpose of Dodd-Frank, but also how it might be reformed. |
Fri, 10 February 2017
We explain why Facebook and Shopify are two tech stocks we really like, and answer Gaby's questions about the companies. Thanks to Audible for supporting our podcast. Get a free audiobook with a free 30 day trial at audible.com/fool. |
Thu, 9 February 2017
There are many green stocks in the marketplace, here are two of the top plays today. Thanks to Thumbtack for supporting Motley Fool. Hire local, skilled pros for just about anything at thumbtack.com today. |
Wed, 8 February 2017
These companies are disrupting their respective industries, and each has catalysts that could reward investors in the future. Is one a better stock to buy than the other? Thanks to Audible for supporting our podcast. Get a free audiobook with a free 30 day trial at audible.com/fool. |
Tue, 7 February 2017
We welcome financials analyst Gaby Lapera to the show to share some of our favorite stocks in the consumer and retail sector. In this case, leading companies in their respective industries can still make for a David and Goliath story. Thanks to Thumbtack for supporting Motley Fool. Hire local, skilled pros for just about anything at thumbtack.com today. |
Mon, 6 February 2017
Listen as two great stocks in the financials sector face off against each other. |
Fri, 3 February 2017
Apple's recent quarterly check-ins have been fairly ho-hum, but not this time! The Mac maker is back to growth after an impressive quarter, we explain what segments pushed the company over the top, and what investors can expect next quarter. |
Thu, 2 February 2017
Forget that power plant off in the distance, these places have wind mills present on the horizon. |
Wed, 1 February 2017
Competitors make headway against Teva Pharmaceutical's top-seller, and Biogen's hemophilia drugs become Bioverativ. Here's what you should know. |